SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:kth-19794"
 

Sökning: onr:"swepub:oai:DiVA.org:kth-19794" > Influence of admini...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003165naa a2200553 4500
001oai:DiVA.org:kth-19794
003SwePub
008100810s2000 | |||||||||||000 ||eng|
024a https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-197942 URI
024a https://doi.org/10.1016/S0264-410X(00)00057-82 DOI
040 a (SwePub)kth
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Goetsch, L.4 aut
2451 0a Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant respiratory syncytial virus subunit vaccine candidate
264 1c 2000
338 a print2 rdacarrier
500 a QC 20100525
520 a The immunogenicity and protective efficacy of BBG2Na, a novel recombinant respiratory syncytial virus subunit vaccine candidate, was assessed in BALB/c mice under various conditions of dose, administration route and number of immunisations. A single intra-peritoneal (i.p.) dose of 2 mu g, or two doses of 0.2 mu g, were sufficient to induce elevated RSV-A serum antibodies and sterilising lung protective immunity. Serum antibody titres were significantly boosted following second immunisations, but not a third. Of three routes of immunisation, i.p. induced the highest RSV-A antibody titres, followed in efficacy by the intramuscular (i.m.) and subcutaneous (s.c.) routes. Nonetheless, all three routes induced comparable and sterilising lung protection. In contrast, upper respiratory tract protection was observed only after i.p. vaccination, although significant viral titre reductions were evident following i.m. or s.c. immunisations. Interestingly, Pepscan analyses indicated that antibody epitope usage was highest in i.p. and lowest in i.m. immunised mice, respectively. Nonetheless, all routes resulted in antibody responses to known lung protective epitopes (protectopes). Thus, the prevention of serious lower respiratory tract disease, the principle goal of a RSV vaccine, but not URT infection, is dose dependent but unlikely to be influenced by the route of BBG2Na administration.
653 a RSV
653 a vaccine
653 a route
653 a subunit
653 a immunogenicity
653 a protective efficacy
653 a g-protein fragment
653 a g fusion protein
653 a balb/c mice
653 a b-cells
653 a immunization
653 a infection
653 a immunity
653 a rsv
653 a glycoprotein
653 a eosinophilia
700a Plotnicky-Gilquin, H.4 aut
700a Champion, T.4 aut
700a Beck, A.4 aut
700a Corvaia, N.4 aut
700a Ståhl, Stefanu KTH,Bioteknologi4 aut0 (Swepub:kth)u1svy8i4
700a Bonnefoy, J. Y.4 aut
700a Nguyen, T. N.4 aut
700a Power, U. F.4 aut
710a KTHb Bioteknologi4 org
773t Vaccineg 18:24, s. 2735-2742q 18:24<2735-2742x 0264-410Xx 1873-2518
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-19794
8564 8u https://doi.org/10.1016/S0264-410X(00)00057-8

Hitta via bibliotek

  • Vaccine (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy